Corey Salsberg, one of the leading voices on intellectual property policy in the United States, joins Clause 8 to discuss surviving the anti-pharma activism of the last administration, why he’s encouraged by the current administration’s approach to patent policy, and even the scientific possibility of “resurrecting the woolly mammoth.”

As Global Head of IP at Novartis, Salsberg has a unique vantage point on how legal uncertainty affects the future of healthcare innovations. His work testifying before Congress has placed him at the center of the debate over the Supreme Court’s Mayo, Myriad, and Alice decisions — rulings that he thinks have been followed by years of instability around Section 101, threatening investment in critical biotech and diagnostic breakthroughs.

The conversation explores the political landscape surrounding the Patent Eligibility Restoration Act (PERA), the persistence of myths like “patent thickets,” and the consequences of letting misinformation shape innovation policy. It also highlights what Congress can do to prevent the U.S. from falling behind in the race for gene and AI-driven therapeutics.

Ultimately, Salsberg’s perspective underscores how constructive, good-faith dialogue across industries remains essential to safeguarding innovation.

🎧 Listen to the full episode now on the Clause 8 Podcast.

📌 Sponsored by Tradespace – where ideas take flight.

✉️ Subscribe to Voice of IP for more stories behind the world’s most consequential innovations:voiceofip.com

Disclaimer

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.voiceofip.com